1Y Close · As of Aug 26, 2026
KoBioLabs operates in the Professional Services sector.
Legal name: KoBioLabs, Inc.
In fiscal year 2025, KoBioLabs (348150) reported revenue of 69.3 billion KRW, up 1.4% from 68.4 billion KRW a year earlier.
Operating profit was -9.7 billion KRW and net income was -7.0 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 59.4 billion KRW, with a P/B of 1.21.
These figures can be verified in the DART filing (receipt no. 20260319000024).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 69.3B | -9.7B | -7.0B |
| 2024 | 68.4B | -6.9B | -4.6B |
| 2023 | 33.1B | -18.5B | -15.2B |
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-13 | Semi-Annual Report (2026.06) |